
C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Investment analysts at Brookline Capital Markets lowered their FY2029 earnings per share estimates for shares of C4 Therapeutics in a research report issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now expects that the company will earn $5.68 per share for the year, down from their previous estimate of $5.90. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.81) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ FY2030 earnings at $21.65 EPS.
Several other analysts have also recently issued reports on the stock. Evercore cut shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Guggenheim initiated coverage on shares of C4 Therapeutics in a report on Friday. They issued a “buy” rating and a $6.00 price objective for the company. Wall Street Zen downgraded shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. JPMorgan Chase & Co. assumed coverage on shares of C4 Therapeutics in a report on Friday, October 9th. They set an “overweight” rating and a $10.00 target price on the stock. Finally, Lake Street Capital assumed coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They set a “buy” rating and a $11.00 target price on the stock. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.
C4 Therapeutics Price Performance
NASDAQ CCCC opened at $3.10 on Monday. The company has a market cap of $381.38 million, a P/E ratio of -4.31 and a beta of 3.16. The stock has a 50-day moving average of $3.22 and a two-hundred day moving average of $3.22. C4 Therapeutics has a 1-year low of $1.69 and a 1-year high of $5.17.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. C4 Therapeutics had a negative return on equity of 37.71% and a negative net margin of 282.22%. The company had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million.
Institutional Trading of C4 Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of CCCC. Velan Capital Investment Management LP purchased a new stake in C4 Therapeutics during the 2nd quarter worth about $2,662,000. Renaissance Technologies LLC boosted its position in shares of C4 Therapeutics by 53.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company’s stock worth $6,475,000 after acquiring an additional 859,235 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of C4 Therapeutics by 18.9% during the 2nd quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company’s stock worth $16,451,000 after acquiring an additional 560,883 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of C4 Therapeutics in the 1st quarter valued at about $1,192,000. Finally, Headlands Technologies LLC purchased a new position in shares of C4 Therapeutics in the 2nd quarter valued at about $719,000. 78.81% of the stock is currently owned by institutional investors and hedge funds.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.
C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.
Recommended Stories
- Five stocks we like better than C4 Therapeutics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
